Effects of Ashwagandha (Roots of Withania somnifera) on neurodegenerative diseases

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 6, 2014, Pages 892-897

  Kuboyama, Tomoharu ^a   Tohda, Chihiro ^a   Komatsu, Katsuko ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Alzheimer's disease; Ashwagandha; Denosomin; Spinal cord injury; Withania somnifera; Withanolide

Indexed keywords

ALPHA SECRETASE; AMYLOID PRECURSOR PROTEIN; ASHWAGANDHA EXTRACT; BETA SECRETASE; DENOSOMIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SCOPOLAMINE; SOMINONE; UNCLASSIFIED DRUG; WITHANIA SOMNIFERA EXTRACT; WITHANOLIDE; WITHANOLIDE A; WITHANOLIDE D; WITHANOSIDE IV; WITHANOSIDE VI; NEUROPROTECTIVE AGENT; PLANT EXTRACT; WITHANIA SOMNIFERA;

ALZHEIMER DISEASE; AYURVEDA; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MENTAL PERFORMANCE; NERVE FIBER GROWTH; NERVE FIBER REGENERATION; NONHUMAN; PLANT ROOT; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REVIEW; SPINAL CORD INJURY; SYNAPSE; UPREGULATION; CHEMICAL STRUCTURE; CHEMISTRY; ISOLATION AND PURIFICATION; NEURODEGENERATIVE DISEASES; PATHOLOGY; SPINAL CORD INJURIES; WITHANIA;

ALZHEIMER DISEASE; HUMANS; MEDICINE, AYURVEDIC; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PLANT EXTRACTS; PLANT ROOTS; SPINAL CORD INJURIES; WITHANIA;

EID: 84901849194     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00022     Document Type: Review

References (60)

1. Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. Neuroscience, 105, 99-107 (2001).
2. Perl DP. Neuropathology of Alzheimer's disease. Mt. Sinai J. Med., 77, 32-42 (2010).
3. Kanaan NM, Pigino GF, Brady ST, Lazarov O, Binder LI, Morfini GA. Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system. Exp. Neurol., 246, 44-53 (2013).
4. McKeon RJ, Schreiber RC, Rudge JS, Silver J. Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. J. Neurosci., 11, 3398-3411 (1991).
5. Silver J, Miller JH. Regeneration beyond the glial scar. Nat. Rev. Neurosci., 5, 146-156 (2004).
6. Jones LL, Tuszynski MH. Spinal cord injury elicits expression of keratan sulfate proteoglycans by macrophages, reactive microglia, and oligodendrocyte progenitors. J. Neurosci., 22, 4611-4624 (2002).
7. Imagama S, Sakamoto K, Tauchi R, Shinjo R, Ohgomori T, Ito Z, Zhang H, Nishida Y, Asami N, Takeshita S, Sugiura N, Watanabe H, Yamashita T, Ishiguro N, Matsuyama Y, Kadomatsu K. Keratan sulfate restricts neural plasticity after spinal cord injury. J. Neurosci., 31, 17091-17102 (2011).
8. Davies SJ, Fitch MT, Memberg SP, Hall AK, Raisman G, Silver J. Regeneration of adult axons in white matter tracts of the central nervous system. Nature, 390, 680-683 (1997).
9. Tom VJ, Steinmetz MP, Miller JH, Doller CM, Silver J. Studies on the development and behavior of the dystrophic growth cone, the hallmark of regeneration failure, in an in vitro model of the glial scar and after spinal cord injury. J. Neurosci., 24, 6531-6539 (2004).
10. Yiu G, He Z. Glial inhibition of CNS axon regeneration. Nat. Rev. Neurosci., 7, 617-627 (2006).
11. Sivarajan VV, Balachandran I. Ayurvedic drugs and their plant sources. International Science Publisher, New York (1994).
12. Warrier PK, Nambiar VPK, Ramankutty C. Indian Medicinal Plants: A Compendium of 500 Species. Orient Longman, Madras, India (1996).
13. Usmanghani K, Saeed A, Alam MT. Indusyunic medicine: traditional medicine of herbal, animal, and mineral origin in Pakistan. Dept. of Pharmacognosy, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan (1997).
14. Kulkarni SK, Dhir A. Withania somnifera: an Indian ginseng. Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, 1093-1105 (2008).
15. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern. Med. Rev., 5, 334-346 (2000).
16. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol., 30, 572-580 (1991).
17. Tohda C, Kuboyama T, Komatsu K. Dendrite extension by methanol extract of Ashwagandha (roots of Withania somnifera) in SK-N-SH cells. Neuroreport, 11, 1981-1985 (2000).
18. Zhao J, Nakamura N, Hattori M, Kuboyama T, Tohda C, Komatsu K. Withanolide derivatives from the roots of Withania somnifera and their neurite outgrowth activities. Chem. Pharm. Bull., 50, 760-765 (2002).
19. Kuboyama T, Tohda C, Zhao J, Nakamura N, Hattori M, Komatsu K. Axon- or dendrite-predominant outgrowth induced by constituents from Ashwagandha. Neuroreport, 13, 1715-1720 (2002).
20. Yankner BA, Dawes LR, Fisher S, Villa-Komaroff L, Oster-Granite ML, Neve RL. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science, 245, 417-420 (1989).
21. Kuboyama T, Tohda C, Komatsu K. Neuritic regeneration and synaptic reconstruction induced by withanolide A. Br. J. Pharmacol., 144, 961-971 (2005).
22. Kuboyama T, Tohda C, Komatsu K. Withanoside IV and its active metabolite, sominone, attenuate A beta(25-35)-induced neurodegeneration. Eur. J. Neurosci., 23, 1417-1426 (2006).
23. Tohda C, Komatsu K, Kuboyama T. Scientific basis for the antidementia drugs of constituents from Ashwagandha (Withania somnifera). J. Trad. Med., 22, 176-182 (2005).
24. Akao T, Hayashi T, Kobashi K, Kanaoka M, Kato H, Kobayashi M, Takeda S, Oyama T. Intestinal bacterial hydrolysis is indispensable to absorption of 18 beta-glycyrrhetic acid after oral administration of glycyrrhizin in rats. J. Pharm. Pharmacol., 46, 135-137 (1994).
25. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab. Dispos., 31, 1065-1071 (2003).
26. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci., 26, 10129-10140 (2006).
27. Joyashiki E, Matsuya Y, Tohda C. Sominone improves memory impairments and increases axonal density in Alzheimer's disease model mice, 5XFAD. Int. J. Neurosci., 121, 181-190 (2011).
28. Tohda C, Joyashiki E. Sominone enhances neurite outgrowth and spatial memory mediated by the neurotrophic factor receptor, RET. Br. J. Pharmacol., 157, 1427-1440 (2009).
29. Durbec P, Marcos-Gutierrez CV, Kilkenny C, Grigoriou M, Wartiowaara K, Suvanto P, Smith D, Ponder B, Costantini F, Saarma M, Sariola H, Pachnis V. GDNF signalling through the Ret receptor tyrosine kinase. Nature, 381, 789-793 (1996).
30. Trupp M, Arenas E, Fainzilber M, Nilsson AS, Sieber BA, Grigoriou M, Kilkenny C, Salazar-Grueso E, Pachnis V, Arumäe U, Sariola H, Saarma M, Ibáñez CF. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature, 381, 785-789 (1996).
31. Patil SP, Maki S, Khedkar SA, Rigby AC, Chan C. Withanolide A and asiatic acid modulate multiple targets associated with amyloid-beta precursor protein processing and amyloid-beta protein clearance. J. Nat. Prod., 73, 1196-1202 (2010).
32. Prox J, Rittger A, Saftig P. Physiological functions of the amyloid precursor protein secretases ADAM10, BACE1, and presenilin. Exp. Brain Res., 217, 331-341 (2012).
33. Kurapati KR, Atluri VS, Samikkannu T, Nair MP. Ashwagandha (Withania somnifera) reverses beta-amyloidl-42 induced toxicity in human neuronal cells: Implications in HIV-associated neurocognitive disorders (HAND). PLoS ONE, 8, e77624 (2013).
34. Widodo N, Kaur K, Shrestha BG, Takagi Y, Ishii T, Wadhwa R, Kaul SC. Selective killing of cancer cells by leaf extract of Ashwagandha: identification of a tumor-inhibitory factor and the first molecular insights to its effect. Clin. Cancer Res., 13, 2298-2306 (2007).
35. Konar A, Shah N, Singh R, Saxena N, Kaul SC, Wadhwa R, Thakur MK. Protective role of Ashwagandha leaf extract and its component withanone on scopolamine-induced changes in the brain and brain-derived cells. PLoS ONE, 6, e27265 (2011).
36. Klinkenberg I, Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci. Biobehav. Rev., 34, 1307-1350 (2010).
37. Hsieh MT, Hsieh CL, Lin LW, Wu CR, Huang GS. Differential gene expression of scopolamine-treated rat hippocampus-application of cDNA microarray technology. Life Sci., 73, 1007-1016 (2003).
38. Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc. Nail. Acad. Sci. U.S.A., 109, 3510-3515 (2012).
39. Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fulop L, Penke B, Zilberter Y, Harkany T, Pitkanen A, Tanila H. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J. Neurosci., 29, 3453-3462 (2009).
40. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV. Clearance of Alzheimer's amyloid-ss(l-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest., 106, 1489-1499 (2000).
41. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron, 43, 333-344 (2004).
42. von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM, Spoelgen R, Hshieh TT, Ranganathan S, Battey FD, Liu CX, Bacskai BJ, Sever S, Irizarry MC, Strickland DK, Hyman BT. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J. Biol. Chem., 280, 17777-17785 (2005).
43. Nakayama N, Tohda C. Withanoside IV improves hindlimb function by facilitating axonal growth and increase in peripheral nervous system myelin level after spinal cord injury. Neurosci. Res., 58, 176-182 (2007).
44. Matsuya Y, Yamakawa Y, Tohda C, Teshigawara K, Yamada M, Nemoto H. Synthesis of sominone and its derivatives based on an RCM strategy: discovery of a novel anti-Alzheimer's disease medicine candidate "denosomin." Org. Lett., 11, 3970-3973 (2009).
45. Teshigawara K, Kuboyama T, Shigyo M, Nagata A, Sugimoto K, Matsuya Y, Tohda C. A novel compound, denosomin, ameliorates spinal cord injury via axonal growth associated with astrocytesecreted vimentin. Br. J. Pharmacol., 168, 903-919 (2013).
46. Sharma S, Dahanukar S, Karandikar SM. Effects of long-term administration of the roots of Ashwagandha (Withania somnifera) and Shatavari (Asparagus racemosus) in rats. Indian Drugs, 23, 133-139 (1986).
47. Prabu PC, Panchapakesan S, Raj CD. Acute and sub-acute oral toxicity assessment of the hydroalcoholic extract of Withania somnifera roots in Wistar rats. Phytother. Res., 27, 1169-1178 (2013).
48. Singh N, Nath R, Lata A, Singh SP, Kohli RP, Bhargava KP. Withania somnifera (Ashwagandha), a rejuvenating herbal drug which enhances survival during stress (an adaptogen). Int. J. Crude Drug Res., 20, 29-35 (1982).
49. Sharada AC, Solomon FE, Devi PU. Toxicity of Withania somnifera root extract in rats and mice. Int. J. Pharmacog., 31, 205-212 (1993).
50. Vanden Berghe W, Sabbe L, Kaileh M, Haegeman G, Heyninck K. Molecular insight in the multifunctional activities of Withaferin A. Biochem. Pharmacol., 84, 1282-1291 (2012).
51. Vyas AR, Singh SV. Molecular targets and mechanisms of cancer prevention and treatment by withaferin A, a naturally occurring steroidal lactone. AAPS J., 16, 1-10 (2014).
52. Mondal S, Mandal C, Sangwan R, Chandra S, Mandal C. Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. Mol. Cancer, 9, 239 (2010).
53. Vaishnavi K, Saxena N, Shah N, Singh R, Manjunath K, Uthayakumar M, Kanaujia SP, Kaul SC, Sekar K, Wadhwa R. Differential activities of the two closely related withanolides, Withaferin A and Withanone: bioinformatics and experimental evidences. PLoS ONE, 7, e44419 (2012).
54. Sharada AC, Solomon FE, Devi PU, Udupa N, Srinivasan KK. Antitumor and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma in vivo. Acta Oncol, 35, 95-100 (1996).
55. Ahmad M, Saleem S, Ahmad AS, Ansari MA, Yousuf S, Hoda MN, Islam F. Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats. Hum. Exp. Toxicol., 24, 137-147 (2005).
56. RajaSankar S, Manivasagam T, Sankar V, Prakash S, Muthusamy R, Krishnamurti A, Surendran S. Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse. J. Ethnopharmacol., 125, 369-373 (2009).
57. Sankar SR, Manivasagam T, Krishnamurti A, Ramanathan M. The neuroprotective effect of Withania somnifera root extract in MPTP-intoxicated mice: an analysis of behavioral and biochemical variables. Cell. Mol. Biol. Lett., 12, 473-481 (2007).
58. RajaSankar S, Manivasagam T, Surendran S. Ashwagandha leaf extract: a potential agent in treating oxidative damage and physiclogical abnormalities seen in a mouse model of Parkinson's disease. Neurosci. Lett., 454, 11-15 (2009).
59. Prakash J, Yadav SK, Chouhan S, Singh SP. Neuroprotective role of Withania somnifera root extract in maneb-paraquat induced mouse model of parkinsonism. Neurochem. Res., 38, 972-980 (2013).
60. Kumar P, Kumar A. Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington's disease. J. Med. Food, 12, 591-600 (2009).